For example, an industry-funded trial examining the insulin sensitizing drug Rosiglitazone in type 2 diabetics demonstrated a highly statistically significant primary surrogate outcome (fasting plasma glucose). The gene discussed is INS; the disease is type 2 diabetes mellitus.